Skip to content
Biopharma Faces Supply Chain Disruptions Amid Geopolitical Instability

Biopharma Faces Supply Chain Disruptions Amid Geopolitical Instability

First seen 31 Oct 2026, 09:41 UTC • •

Article Content

Browse articles
ThreatCluster AI
ThreatCluster •November 1, 2026 at 08:48 UTC
  • •Biopharma companies are reassessing CDMO resilience due to systemic supply chain risks.
  • •Only 22% of pharma firms were evaluating geopolitical risks as of late 2025.
  • •Flexible supply models like Just-in-Time are essential for adapting to disruptions.

Biopharmaceutical companies are increasingly assessing the resilience of contract development and manufacturing organizations (CDMOs) due to systemic risks in supply chains. Disruptions from geopolitical instability, adverse weather, and regulatory changes have exposed vulnerabilities in clinical supply chains. Only 22% of global pharma companies were actively evaluating these risks by the end of 2025. The industry is shifting towards flexible supply models, such as Just-in-Time (JIT) approaches, to adapt to changing demands. Current practices often fail to accommodate the dynamic nature of drug development, leading to inefficiencies and potential delays in delivering therapies to patients. Companies are urged to map vulnerabilities in their supply networks and consider geographic concentration and material dependencies when selecting CDMOs. The need for resilience in supply chains is critical as operational bottlenecks can directly impact clinical development timelines and commercial launch readiness.

Start a free Starter trial for enhanced analysis

Ask AI about this cluster

Updated 14d ago How this analysis works

Timeline

2025-12-31
22% of pharma companies assess geopolitical risks
Research indicates that only a small fraction of global pharma companies were actively evaluating geopolitical risks at the end of 2025.
Contractpharma
Recent
Shift to flexible supply models
The industry is moving towards Just-in-Time supply models to better handle disruptions and changing demands.
Contractpharma

More articles in this cluster (2)

Common questions

What are the main vulnerabilities in biopharma supply chains?
Key vulnerabilities include geographic concentration, material dependencies, and inflexible supply models that do not adapt to changing demands.
How can companies improve supply chain resilience?
Companies should adopt flexible supply models like Just-in-Time and conduct thorough assessments of their CDMO partners' capabilities.
What percentage of pharma companies are assessing geopolitical risks?
As of late 2025, only 22% of global pharma companies were actively assessing geopolitical risks.